Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study
Journal of Clinical Oncology · 2023
DOI: 10.1200/jco.22.02093 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Gianni Bisogno und 19 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy. Hauptthemen laut MEDLINE: Rhabdomyosarcoma, Sarcoma. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: Cancer Research UK.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. The RMS2005 study included two phase III randomized trials for high-risk (HR) and observational trials for low (LR), standard (SR), and very high-risk (VHR) patients who have been partially reported. Herein, we present a comprehensive report of results achieved for the complete unselected nonmetastatic cohort and analyze the evolution of treatment in comparison with previous European protocols. After a median follow-up of 73.1 months, the 5-year event-free survival (EFS) and overall survival (OS) of the 1,733 patients enrolled were 70.7% (95% CI, 68.5 to 72.8) and 80.4% (95% CI, 78.4 to 82.3), respectively. The results by subgroup: LR (80 patients) EFS 93.7% (95% CI, 85.5 to 97.3), OS 96.7% (95% CI, 87.2 to 99.2); SR (652 patients) EFS 77.4% (95% CI, 73.9 to 80.5), OS 90.6% (95% CI, 87.9 to 92.7); HR (851 patients) EFS 67.3% (95% CI, 64.0 to 70.4), OS 76.7% (95% CI, 73.6 to 79.4); and VHR (150 patients) EFS 48.8% (95% CI, 40.4 to 56.7), OS 49.7% (95% CI, 40.8 to 57.9). The RMS2005 study demonstrated that 80% of children with localized rhabdomyosarcoma could be long-term survivors. The study has established the standard of care across the European pediatric Soft tissue sarcoma Study Group countries with the confirmation of a 22-week vincristine/actinomycin D regimen for LR patients, the reduction of the cumulative ifosfamide dose in the SR group, and for HR disease, the omission of doxorubicin and the addition of maintenance chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pediatric Hematology Oncology Division, University Hospital of Padua, Padua, Italy.
- Department of Pediatric and Adolescent Oncology, Gustave-Roussy, Université Paris-Saclay, Villejuif, France.
- Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
- Department of Pediatric Oncology and Hematology, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Radiation Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
ORCID-Profile: Gianni Bisogno, Veronique Minard-Colin, Andrea Ferrari, Soledad Gallego, Raquel Dávila Fajardo, Henry Mandeville, Daniel Orbach, Gabriela Guillén Burrieza, Heidi Glosli, Anne Sophie Defachelles, Johannes Hendrikus Maria Merks
Förderung
- Cancer Research UK
Zitieren
APA
Bisogno, G., Minard-Colin, V., Zanetti, I., Ferrari, A., Gallego, S., Dávila Fajardo, R., Mandeville, H., Kelsey, A., Alaggio, R., Orbach, D., Terwisscha van Scheltinga, S., Guillén Burrieza, G., Ben-Arush, M., Glosli, H., Mudry, P., Ferman, S., Devalck, C., Defachelles, A. S., Merks, J. H. M., & Jenney, M. (2023). Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.02093
Vancouver
Bisogno G, Minard-Colin V, Zanetti I, Ferrari A, Gallego S, Dávila Fajardo R, et al. Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study. Journal of Clinical Oncology. 2023. doi:10.1200/jco.22.02093
BibTeX
@article{Bisogno2023,
author = {Bisogno, Gianni and Minard-Colin, Veronique and Zanetti, Ilaria and Ferrari, Andrea and Gallego, Soledad and Dávila Fajardo, Raquel and Mandeville, Henry and Kelsey, Anna and Alaggio, Rita and Orbach, Daniel and Terwisscha van Scheltinga, Sheila and Guillén Burrieza, Gabriela and Ben-Arush, Myriam and Glosli, Heidi and Mudry, Peter and Ferman, Sima and Devalck, Christine and Defachelles, Anne Sophie and Merks, Johannes Hendrikus Maria and Jenney, Meriel},
title = {Nonmetastatic Rhabdomyosarcoma in Children and Adolescents: Overall Results of the European Pediatric Soft Tissue Sarcoma Study Group RMS2005 Study},
journal = {Journal of Clinical Oncology},
year = {2023},
doi = {10.1200/jco.22.02093}
}
EUVIMED